Clinically supervised GLP-1/GIP protocols — personalized to your labs, dose, and physiology. Licensed providers, ongoing dose optimization, individually compounded for each patient.
Prescription treatment requires provider review. Compounded medications are not FDA-approved.
Compounded GLP-1 medications are not FDA-approved. A medical consultation is required to determine eligibility — not all patients qualify.
The Longevity Score is an educational estimate, not a diagnostic tool.
Your path is based on goals, health history, medications, metabolic risk, available lab context, and provider review — not a one-size-fits-all protocol.
Compare two clinically supervised options. Final treatment depends on eligibility and provider review.
Appetite, cravings, and metabolic support for eligible patients starting with a focused incretin pathway.
Dual-pathway metabolic support for eligible patients who may need a broader incretin approach.
Prescription treatment requires an online medical consultation. Compounded medications are prepared by licensed pharmacies for patient-specific prescriptions and are not FDA-approved commercial products.
Most eligibility decisions start with body metrics, metabolic risk, health history, and medication safety.
No — labs are not required to place your order, as long as you can accurately and completely answer the medical-history questions during intake. Your provider reviews your history and prescribes when appropriate. If you have recent labs (within ~6 months) you may upload them, and a provider can still recommend a panel in some cases, but lab work is optional and not a prerequisite to begin. If ordered, lab costs are not included in the program price — additional charges apply.
The active ingredient is the same — semaglutide is the molecule in both Wegovy and compounded GLP-1 protocols; tirzepatide is the molecule in both Zepbound and compounded GLP-1/GIP protocols. Important context: The FDA officially resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in October 2024. The temporary shortage-based compounding pathway (503B outsourcing) closed in mid-2025, but the patient-specific 503A pathway remains open under longstanding federal law. Compounded medications are prepared by licensed 503A pharmacies on a per-prescription basis under provider supervision; they are not FDA-approved as commercial products. Branded Wegovy and Zepbound (and the new oral Wegovy pill, approved December 2025) are also available through standard pharmacy channels — your provider can help you weigh both options.
No. You only pay if a provider determines you're eligible and writes a prescription. The intake itself is free, and there's no charge if you don't qualify or if you change your mind before your first shipment is dispatched.
The most common side effects are gastrointestinal — nausea, constipation, or diarrhea — particularly during dose increases. Most resolve within 1–2 weeks. The titration ladder we use specifically minimizes side effects by allowing your body to adjust gradually. Your provider will adjust your dose if side effects are persistent.
Yes. There's no long-term contract. You can pause or cancel future shipments through your account at any time before the next shipment processes. Already-shipped orders cannot be returned per pharmacy regulations.
The program price includes your provider consultation and medication, plus prescription writing, dose adjustments, fulfillment from a licensed 503A pharmacy, and ongoing provider access for questions or side-effect management. Shipping is a separate $20 flat rate per order, nationwide. Any lab work, if ordered, is billed separately.
Compounded GLP-1 medications are not reviewed or approved by the FDA. A medical consultation is required to determine eligibility, and not all patients qualify. Service availability varies by state. Treatment decisions are made by a licensed provider based on medical history, current medications, contraindications, and available lab context when needed.
Find out whether GLP-1 care or GLP-1/GIP may fit your goals after eligibility and provider review.
Programs start at $149. Includes provider consultation, prescription, medication fulfillment, and ongoing support. Order as needed — no pressure, no auto-shipping. Shipping is a separate add-on ($20 flat rate nationwide) and required labs are billed separately.
GLP-1 receptor agonist. Reduces appetite, slows gastric emptying, and improves insulin sensitivity.
Activates GLP-1 receptors to slow gastric emptying, increase satiety, and improve glucose regulation.
Dual GIP + GLP-1 receptor agonist. Activates two appetite-regulating pathways for additive metabolic effects.
Activates both GIP and GLP-1 receptors for additive effects on appetite regulation and metabolic flexibility.
Most adults qualify for at least one program. The intake takes about 5 minutes and includes a health questionnaire, body metrics, and recent labs (we'll order them if you don't have any).
A medical consultation is required to determine eligibility. Not all patients qualify for compounded GLP-1 therapy.
Check Your Eligibility→You meet either of these criteria — most patients qualify under #1:
No clinic visits. No insurance hassles. Three steps from start to first shipment.
Answer a 5-minute health questionnaire covering your medical history, current medications, body metrics, and goals. Upload recent labs or we'll order them.
A licensed provider reviews your intake, may request a brief async consult or video visit, and writes your prescription if you qualify. You'll never pay for a denied prescription.
Your medication ships from a licensed 503A compounding pharmacy with everything you need — vial, syringes, and dosing instructions.
Answer a few questions about your health, biomarkers, and goals. Get a personalized Longevity Score, biological age, and a recommendation matched to your data.
Most weight-related disease starts a decade before diagnosis. Catching it early — and treating it with the right medication — can change that trajectory. Start with a free assessment, or check your eligibility for GLP-1 directly.
